AMB-05X clinical trials

A Phase 2, Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects with Tenosynovial Giant Cell Tumor

This study is testing a new medicine called AMB-05X for a condition called Tenosynovial Giant Cell Tumor (TGCT). It's looking at how safe and effective the medicine is, how well people tolerate it, and how it works in the body. Researchers want to see if it shrinks the tumor.